FDA Accepts Aquestive’s Anaphylm Resubmission for Review

Bitget2026/10/15 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis.
The Class 2 review has a target decision date of March 16, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150700PRIMZONEFULLFEED9846192) on October 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA Accepts Aquestive’s Anaphylm Resubmission for Review

You may also like

Crypto prices